News #CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information #CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information by Patricia Silva, PhD | June 3, 2016 Share this article: Share article via email Copy article link People with primary progressive multiple sclerosis (PPMS) are usually older and more disabled than those with relapsing-remitting MS, researchers at Washington University reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in the NARCOMS registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, “The Profile of a Contemporary Cohort of Participants with Primary Progressive Multiple Sclerosis in the NARCOMS Registry” was presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting, taking place in National Harbor, Maryland, through June 4. PPMS differs in several aspects from the far more common relapsing-remitting (RR) form of MS, both in terms of probable underlying disease mechanisms and regarding prognosis and treatment. As a result of the skewed proportion of the disease types, most research also focuses on RRMS, and much more is known about RRMS patients than those with PPMS. NARCOMS is a global registry for MS research, treatment, and patient education, in part supported by CMSC and its Foundation. The registry uses semiannual surveys to gather comprehensive data about demographic and clinical characteristics of its patients. The presentation on June 3, opening a Platform Session called “Comprehensive Care in MS and Symptom Management” and sponsored by Genentech, was based on analyses of self-reported data from patients who participated in the spring 2015 survey. Among the 8,004 participants, 632 (7.9 percent) reported that they were suffering from PPMS. This group was largely women (62.7 percent), and most reported becoming ill at an average age of 36. These people were now, on average, 64.3 years old. A vast majority (94 percent) were Caucasians, and many (89 percent) in the PPMS group were also unemployed. Only 9 percent reported to smoke tobacco. The median Patient-Determined Disease Steps (PDDS) score, a measure of patient-reported disability, was 6, equaling a need for bilateral support. Half of the group fell within the range of 5 (late cane support) to 7 (wheelchair or scooter use). Most patients, 80.5 percent, reported fatigue, and many also had impaired hand function. During the six months preceding the survey, 13.1 percent had a relapse, while 66.9 percent reported a worsening in disease symptoms. Also, 19.7 percent sought emergency care, and 13.8 percent were hospitalized during this period. A quarter of the hospitalizations were caused by a urinary tract infection. The most commonly reported other disease conditions were high blood pressure, high cholesterol, depression, and osteoporosis (brittle bones), affecting a large proportion of the patients. Most MS patients who reported comorbid diseases were receiving treatment for them. “As expected, registry participants with PPMS were older and more disabled than typically reported by persons with relapsing-remitting MS,” the researchers concluded. The team suggested that further studies should be conducted on the various aspects of PPMS patient characteristics, in order to better understand this form of MS, and assist in the development of effective therapies for this patient population. Print This Page About the Author Patricia Silva, PhD Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags cmsc16, disability, Genentech, NARCOMS, PPMS, survey
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada